Description:

Pirfenidone tablet IP 267mg  is a film-coated oral tablet containing the active ingredient pirfenidone. It is an antifibrotic medication used to treat idiopathic pulmonary fibrosis (IPF), a chronic lung disease that causes scarring (fibrosis) in the lungs, making breathing difficult. This generic version (often marketed as Pulmofib or similar by MSN Laboratories) helps slow the progression of lung scarring and decline in lung function.

Prescription:

• Yes, prescription-only medicine.

Therapeutic Category:

• Antifibrotic agent

Active Ingredients/Composition:

• Active ingredient: Pirfenidone 267 mg per tablet.

Variant:

• This is the 267 mg strength tablet (standard starting dose tablet). Higher strengths include 534 mg and 801 mg tablets. It is often the IP (Indian Pharmacopoeia) compliant generic version.

Consume Type:

• Oral (taken by mouth as a tablet with food).

Directions/Usage:

Take with food to improve tolerability and reduce gastrointestinal side effects. Standard titration (gradual increase to minimize side effects):

• Days 1–7: 267 mg three times a day (total 801 mg/day).
• Days 8–14: 534 mg three times a day (total 1602 mg/day).
• Day 15 onward (maintenance): 801 mg three times a day (total 2403 mg/day), which can use one 801 mg tablet or three 267 mg tablets per dose. Always follow your doctor’s exact instructions. Do not crush or chew; swallow whole. Regular monitoring (liver function tests, etc.) is required.

Common Side Effects:

• Nausea, vomiting, diarrhea, stomach upset/abdominal pain, loss of appetite, weight loss, fatigue, headache, dizziness, upper respiratory tract infections, photosensitivity (increased sun sensitivity leading to rash/burn), itching/rash. Gastrointestinal effects are often reduced by taking with food.

Package Type:

• Typically blister packs

Storage Advice:

• Store at room temperature (below 25–30°C), in a dry place, protected from light and moisture. Keep out of reach of children. Do not use after expiry date.

Safety Advice:

• Avoid if allergic to pirfenidone or with severe liver disease. Regular liver function tests are essential (may cause elevated liver enzymes). Avoid strong sunlight/UV exposure—use sunscreen (SPF 50+), protective clothing, and limit sun exposure. Avoid smoking and alcohol. Inform your doctor of other medications (e.g., fluvoxamine, ciprofloxacin increase levels; avoid strong CYP1A2 inhibitors). Not for use in pregnancy/breastfeeding. Monitor for serious effects like liver problems (jaundice, dark urine) or severe rash—seek immediate medical help if they occur. Not effective for other lung conditions.

Product Substitutes:

• Other generic pirfenidone 267 mg tablets (e.g., Pirfenex by Cipla, Pirfact, Pirfetab, or branded Esbriet). Equivalent 267 mg formulations from other manufacturers like Novadoz, Apotex, or MSN’s Pulmofib.

Manufacturer/Marketer:

• MSN Laboratories (MSN Labs)

Country of Origin:

• India